XML 58 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Net Income Per Limited Partner Unit (Tables)
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Distributions By Partner By Class
For the three and nine months ended September 30, 2020 and 2019, MPLX had dilutive potential common units consisting of certain equity-based compensation awards. Potential common units omitted from the diluted earnings per unit calculation for the three and nine months ended September 30, 2020 and 2019 were less than 1 million.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(In millions)
2020
 
2019
 
2020
 
2019
Net income/(loss) attributable to MPLX LP
$
665

 
$
629

 
$
(1,411
)
 
$
1,614

Less: Distributions declared on Series A preferred units(1)
20

 
20

 
61

 
61

Distributions declared on Series B preferred units(1)
10

 
10

 
31

 
31

Limited partners’ distributions declared on MPLX common units (including common units of general partner)(1)(2)
715

 
704

 
2,158

 
1,919

Undistributed net loss attributable to MPLX LP
$
(80
)

$
(105
)
 
$
(3,661
)
 
$
(397
)

(1)
See Note 7 for distribution information.
(2)
The three and nine months ended September 30, 2019 amounts are net of $12.5 million and $25 million, respectively, of waived distributions with respect to units held by MPC and its affiliates.
 
Three Months Ended September 30, 2020
(In millions, except per unit data)
Limited Partners’
Common Units
 
Series A Preferred Units
 
Series B Preferred Units
 
Total
Basic and diluted net income attributable to MPLX LP per unit
 
 
 
 
 
 
 
Net income attributable to MPLX LP:
 
 
 
 
 
 
 
Distributions declared
$
715

 
$
20

 
$
10

 
$
745

Undistributed net loss attributable to MPLX LP
(80
)
 

 

 
(80
)
Net income attributable to MPLX LP(1)
$
635

 
$
20

 
$
10

 
$
665

Weighted average units outstanding:
 
 
 
 
 
 
 
Basic
1,046

 
 
 
 
 

Diluted
1,047

 
 
 
 
 

Net income attributable to MPLX LP per limited partner unit:
 
 
 
 
 
 
 
Basic
$
0.61

 
 
 
 
 
 
Diluted
$
0.61

 
 
 
 
 
 

Schedule of Basic and Diluted Earnings Per Unit
 
Three Months Ended September 30, 2020
(In millions, except per unit data)
Limited Partners’
Common Units
 
Series A Preferred Units
 
Series B Preferred Units
 
Total
Basic and diluted net income attributable to MPLX LP per unit
 
 
 
 
 
 
 
Net income attributable to MPLX LP:
 
 
 
 
 
 
 
Distributions declared
$
715

 
$
20

 
$
10

 
$
745

Undistributed net loss attributable to MPLX LP
(80
)
 

 

 
(80
)
Net income attributable to MPLX LP(1)
$
635

 
$
20

 
$
10

 
$
665

Weighted average units outstanding:
 
 
 
 
 
 
 
Basic
1,046

 
 
 
 
 

Diluted
1,047

 
 
 
 
 

Net income attributable to MPLX LP per limited partner unit:
 
 
 
 
 
 
 
Basic
$
0.61

 
 
 
 
 
 
Diluted
$
0.61

 
 
 
 
 
 

(1)
Allocation of net income attributable to MPLX LP assumes all earnings for the period had been distributed based on the distribution priorities applicable to the period.


 
Three Months Ended September 30, 2019
(In millions, except per unit data)
Limited Partners’
Common Units
 
Series A Preferred Units
 
Series B Preferred Units
 
Total
Basic and diluted net income attributable to MPLX LP per unit
 
 
 
 
 
 
 
Net income attributable to MPLX LP:
 
 
 
 
 
 
 
Distributions declared
$
704

 
$
20

 
$
10

 
$
734

Undistributed net loss attributable to MPLX LP
(105
)
 

 

 
(105
)
Net income attributable to MPLX LP(1)
$
599

 
$
20

 
$
10

 
$
629

Weighted average units outstanding:
 
 
 
 
 
 
 
Basic(2)
974

 
 
 
 
 

Diluted(2)
975

 
 
 
 
 

Net income attributable to MPLX LP per limited partner unit:
 
 
 
 
 
 
 
Basic
$
0.61

 


 
 
 
 
Diluted
$
0.61

 


 
 
 
 
(1)
Allocation of net income attributable to MPLX LP assumes all earnings for the period had been distributed based on the distribution priorities applicable to the period.
(2)
The Series B preferred units and the MPLX common units issued in connection with the Merger were not outstanding during the entire three months ended September 30, 2019. See Notes 3 and 7 for additional information about the treatment of these units.

 
Nine Months Ended September 30, 2020
(In millions, except per unit data)
Limited Partners’
Common Units
 
Series A Preferred Units
 
Series B Preferred Units
 
Total
Basic and diluted net income attributable to MPLX LP per unit
 
 
 
 
 
 
 
Net income attributable to MPLX LP:
 
 
 
 
 
 
 
Distributions declared
$
2,158

 
$
61

 
$
31

 
$
2,250

Undistributed net loss attributable to MPLX LP
(3,661
)
 

 

 
(3,661
)
Net (loss)/income attributable to MPLX LP(1)
$
(1,503
)
 
$
61

 
$
31

 
$
(1,411
)
Weighted average units outstanding:
 
 
 
 
 
 
 
Basic
1,054

 
 
 
 
 
 
Diluted
1,054

 
 
 
 
 
 
Net income attributable to MPLX LP per limited partner unit:
 
 
 
 
 
 
 
Basic
$
(1.43
)
 
 
 
 
 
 
Diluted
$
(1.43
)
 
 
 
 
 
 
(1)
Allocation of net income attributable to MPLX LP assumes all earnings for the period had been distributed based on the distribution priorities applicable to the period.

 
Nine Months Ended September 30, 2019
(In millions, except per unit data)
Limited Partners’
Common Units
 
Series A Preferred Units
 
Series B Preferred Units
 
Total
Basic and diluted net income attributable to MPLX LP per unit
 
 
 
 
 
 
 
Net income attributable to MPLX LP:
 
 
 
 
 
 
 
Distributions declared
$
1,919

 
$
61

 
$
31

 
$
2,011

Undistributed net loss attributable to MPLX LP
(397
)
 

 

 
(397
)
Net income attributable to MPLX LP(1)
$
1,522

 
$
61

 
$
31

 
$
1,614

Weighted average units outstanding:
 
 
 
 
 
 
 
Basic(2)
855

 
 
 
 
 
 
Diluted(2)
855

 
 
 
 
 
 
Net income attributable to MPLX LP per limited partner unit:
 
 
 
 
 
 
 
Basic
$
1.78

 
 
 
 
 
 
Diluted
$
1.78

 
 
 
 
 
 

(1)
Allocation of net income attributable to MPLX LP assumes all earnings for the period had been distributed based on the distribution priorities applicable to the period.
(2)
The Series B preferred units and the MPLX common units issued in connection with the Merger were not outstanding during the entire nine months ended September 30, 2019. See Notes 3 and 7 for additional information about the treatment of these units.